Galderma presents new data at AAD meeting that demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis.
Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study
Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).
These late-breaking data are being presented at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.
“We’re excited to see the evidence base for nemolizumab continue to build and strengthen for these debilitating diseases, where symptoms such as intense itch can put a significant burden on quality of life. Having already demonstrated nemolizumab’s efficacy and rapid onset of action, these new results show its long-term benefit and durability of response in prurigo nodularis and atopic dermatitis, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins